Journal
ANTIOXIDANTS
Volume 9, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/antiox9020133
Keywords
ovarian cancer; chemoresistance; l-buthionine sulfoximine; polyurea dendrimers; carboplatin; nanoparticles-mediated chemotherapy; chemosensitization
Funding
- Fundacao para a Ciencia e a Tecnologia-Ministerio da Educacao e Ciencia (FCT-MCTES) [iNOVA4Health-UID/Multi/04462]
- FEDER under the PT2020 Partnership Agreement
- FCT-MCTES [DREAM-PTDC/MEC-ONC/29327/2017]
- FAI2017 from IPOLFG
Ask authors/readers for more resources
Ovarian cancer is a highly lethal disease, mainly due to chemoresistance. Our previous studies on metabolic remodeling in ovarian cancer have supported that the reliance on glutathione (GSH) bioavailability is a main adaptive metabolic mechanism, also accounting for chemoresistance to conventional therapy based on platinum salts. In this study, we tested the effects of the in vitro inhibition of GSH synthesis on the restoration of ovarian cancer cells sensitivity to carboplatin. GSH synthesis was inhibited by exposing cells to l-buthionine sulfoximine (l-BSO), an inhibitor of gamma-glutamylcysteine ligase (GCL). Given the systemic toxicity of l-BSO, we developed a new formulation using polyurea (PURE) dendrimers nanoparticles (l-BSO@PUREG4-FA(2)), targeting l-BSO delivery in a folate functionalized nanoparticle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available